TriSalus Life Sciences, Inc.
TLSI
$4.76
$0.030.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.73% | -2.92% | 59.85% | 57.38% | 52.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.73% | -2.92% | 59.85% | 57.38% | 52.27% |
| Cost of Revenue | -16.32% | -17.73% | 44.90% | 89.84% | 97.59% |
| Gross Profit | 5.19% | -0.04% | 62.43% | 52.25% | 45.86% |
| SG&A Expenses | 26.79% | 7.38% | 4.10% | 24.23% | 31.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.42% | 4.93% | 4.01% | 27.92% | 19.35% |
| Operating Income | -33.84% | -14.76% | 56.85% | -3.15% | 10.30% |
| Income Before Tax | -10.76% | 114.88% | 3.52% | -349.88% | -91.70% |
| Income Tax Expenses | 233.33% | -20.00% | 100.00% | 266.67% | -142.86% |
| Earnings from Continuing Operations | -10.85% | 114.83% | 3.51% | -350.65% | -91.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.85% | 114.83% | 3.51% | -350.65% | -91.32% |
| EBIT | -33.84% | -14.76% | 56.85% | -3.15% | 10.30% |
| EBITDA | -35.02% | -15.64% | 57.43% | -3.44% | 10.19% |
| EPS Basic | 42.40% | 107.57% | 47.33% | -693.54% | -27.43% |
| Normalized Basic EPS | 48.59% | 66.54% | 70.78% | -72.31% | 63.74% |
| EPS Diluted | 41.52% | 107.54% | 47.33% | -693.54% | -27.43% |
| Normalized Diluted EPS | 48.59% | 66.54% | 70.78% | -72.31% | 63.74% |
| Average Basic Shares Outstanding | 77.20% | 83.38% | 70.03% | 62.47% | 37.63% |
| Average Diluted Shares Outstanding | 77.20% | 83.38% | 70.03% | 62.47% | 37.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |